
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Endocrinol</journal-id><journal-id journal-id-type="iso-abbrev">Int J Endocrinol</journal-id><journal-id journal-id-type="publisher-id">IJE</journal-id><journal-title-group><journal-title>International Journal of Endocrinology</journal-title></journal-title-group><issn pub-type="ppub">1687-8337</issn><issn pub-type="epub">1687-8345</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">20706676</article-id><article-id pub-id-type="pmc">2913672</article-id><article-id pub-id-type="doi">10.1155/2010/945053</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Alterations in Lipids and Adipocyte Hormones in Female-to-Male Transsexuals</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Chandra</surname><given-names>Prakash</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Basra</surname><given-names>Sukhdeep S.</given-names></name><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Tai C.</given-names></name><xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Tangpricha</surname><given-names>Vin</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib></contrib-group><aff id="I1"><sup>1</sup>Division of Endocrinology, Metabolism and Lipids, Department of Medicine, Woodruff Memorial Research Building, Room 1301, 101 Woodruff Circle NE, Atlanta, GA 30322, USA</aff><aff id="I2"><sup>2</sup>School of Public Health, University of Texas at Houston, Houston, TX 77030, USA</aff><aff id="I3"><sup>3</sup>Section of Endocrinology, Diabetes and Nutrition, Department of Medicine, Boston University School of Medicine, Boston, MA 02118, USA</aff><author-notes><corresp id="cor1">*Vin Tangpricha: <email>vin.tangpricha@emory.edu</email></corresp><fn fn-type="other"><p>Academic Editor: Mario Maggi</p></fn></author-notes><pub-date pub-type="ppub"><year>2010</year></pub-date><pub-date pub-type="epub"><day>18</day><month>7</month><year>2010</year></pub-date><volume>2010</volume><elocation-id>945053</elocation-id><history><date date-type="received"><day>12</day><month>1</month><year>2010</year></date><date date-type="rev-recd"><day>6</day><month>4</month><year>2010</year></date><date date-type="accepted"><day>9</day><month>6</month><year>2010</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2010 Prakash Chandra et al.</copyright-statement><copyright-year>2010</copyright-year><copyright-holder>Copyright &#x000a9; 2010 Prakash Chandra et al.</copyright-holder><license xlink:href="https://creativecommons.org/licenses/by/3.0/"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>Testosterone therapy in men and women results in decreased high-density lipoprotein cholesterol (HDL) and increased low-density lipoprotein cholesterol (LDL). We sought to determine whether testosterone therapy has this same effect on lipid parameters and adipocyte hormones in female-to-male (FTM) transsexuals. Twelve FTM transsexuals provided a fasting lipid profile including serum total cholesterol, HDL, LDL, and triglycerides prior to and after 1 year of testosterone therapy (testosterone enanthate or cypionate 50&#x02013;125&#x02009;mg IM every two weeks). Subjects experienced a significant decrease in mean serum HDL (52 &#x000b1; 11
to 40 &#x000b1; 7&#x02009;mg/dL) (<italic>P</italic> &#x0003c; .001). The mean LDL (<italic>P</italic> = .316), triglyceride (<italic>P</italic> = .910), and total cholesterol (<italic>P</italic> = .769) levels remained unchanged. In a subset of subjects, we measured serum leptin levels which were reduced by 25% but did not reach statistical significance (<italic>P</italic> = .181) while resistin levels remained unchanged. We conclude that testosterone therapy in FTM transsexuals can promote an increased atherogenic lipid profile by lowering HDL and possibly reduce serum leptin levels. However, long-term studies are needed to determine whether decreases in HDL result in adverse cardiovascular outcomes.</p></abstract></article-meta></front><body><sec id="sec1"><title>1. Introduction</title><p>Transsexualism is a medical condition characterized by gender dysphoria which is managed with cross-sex hormones and surgery to align an individual's physical appearance with their gender orientation [<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>]. Female-to-male (FTM) transsexuals take testosterone to change into a more masculine phenotype. Current guidelines remain uncertain about long effects of testosterone therapy on cardiovascular outcomes due to lack of long-term studies and suggest risk factors including lipids to be managed individually [<xref rid="B1" ref-type="bibr">1</xref>]. A recent meta-analysis of ten studies of testosterone therapy in FTM transsexuals by Elamin et al. demonstrated increased serum triglycerides (TG) and reduced high-density lipoprotein (HDL) concentrations. However, the data remained unclear about testosterone's effects on other lipid fractions and blood pressure [<xref rid="B3" ref-type="bibr">3</xref>]. Other studies not examined in the meta-analysis by Elamin et al. have demonstrated increased total cholesterol (TC) [<xref rid="B4" ref-type="bibr">4</xref>] and low-density lipoprotein (LDL) levels [<xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B5" ref-type="bibr">5</xref>] in FTM transsexuals receiving testosterone therapy. Similarly, 17 FTM transsexuals treated with intramuscular injections of long acting testosterone undecanonate for 36 months demonstrated a decrease in TC and LDL without effecting triglyceride and HDL levels [<xref rid="B6" ref-type="bibr">6</xref>]. </p><p>Gooren et al. [<xref rid="B7" ref-type="bibr">7</xref>] suggested that an increased atherogenic lipid profile can be a result increased weight and visceral fat after testosterone therapy in FTM transsexuals [<xref rid="B8" ref-type="bibr">8</xref>]. This changed adiposity pattern can lead to differential adipocyte hormone secretion [<xref rid="B9" ref-type="bibr">9</xref>, <xref rid="B10" ref-type="bibr">10</xref>]. However, studies evaluating the effect of testosterone therapy on adipocyte hormones in FTM transsexuals are minimal and available data remain inconclusive. While Elbers et al. [<xref rid="B11" ref-type="bibr">11</xref>] reported supraphysiological doses of testosterone in FTM to reduce leptin levels; others have failed to confirm this finding [<xref rid="B12" ref-type="bibr">12</xref>]. Similarly, the effect of supraphysiologic doses of testosterone administration on resistin still remains to be understood though endogenous androgens in Polycystic Ovarian Syndrome (PCOS) have been shown to cause elevated resistin levels after controlling for body mass [<xref rid="B13" ref-type="bibr">13</xref>].</p><p>We hypothesized that supraphysiologic (male replacement) doses of testosterone in FTM transsexuals (genetic females) would lead to a more atherogenic lipid profile and increase markers of insulin resistance. Our prospective clinical trial evaluated changes in the lipid profile and the adipokines, resistin and leptin, in FTM transsexuals before and after treatment with male-replacement doses of testosterone.</p></sec><sec id="sec2"><title>2. Methods</title><p>
The study was approved by the Boston University School of Medicine IRB and was conducted at the Boston University General Clinical Research Clinic (GCRC).</p><sec sec-type="subsection" id="sec2.1"><title>2.1. Study Subjects</title><p>Subjects were recruited from the endocrinology clinics at Boston University as previously described [<xref rid="B14" ref-type="bibr">14</xref>]. Briefly, all subjects were genetic females who were deemed to have gender identity disorder by their mental health provider and were recommended for treatment with testosterone therapy. For this study, we evaluated subjects who had not previously received testosterone therapy and were analyzed prior to sex reversal surgery.</p></sec><sec sec-type="subsection" id="sec2.2"><title>2.2. Procedures</title><p>We prospectively monitored the serum lipoprotein profile of 12 FTM transsexuals who were started on supraphysiologic doses of testosterone esters, cypionate, or enanthate (supraphysiologic for a female but replacement levels for a male) (50&#x02013;125&#x02009;mg every two weeks to attain male physiological levels of serum testosterone), for 12 months. Subjects provided a fasting blood sample for TC, LDL, LDL, HDL, and triglyceride measurements at baseline and 1 year after initiating testosterone therapy. Due to sample availability, we measured serum resistin and leptin levels only in a subset of subjects (<italic>n</italic> = 5) at baseline and at least 6 to 12 months after initiation of testosterone therapy.</p><p>Cholesterol, glucose, hematocrit, and total testosterone were measured by a commercial laboratory (Quest Diagnostics, (San Juan Capistrano, CA). The resistin and leptin levels were drawn at the same time as the testosterone and at the &#x0201c;trough&#x0201d; level of testosterone. Leptin and Resistin were measured using commercially available ELISA kits from ALPCO Diagnostics (Salem, New Hampshire). The intra- and inter-assay CVs for the Leptin ELISA were 3.7%&#x02013;5.5% and 5.8%&#x02013;6.9%, respectively. The intra- and inter-assay CVs for the resistin ELISA were 2.9%&#x02013;5.2% and 4.2%&#x02013;7.2%, respectively.</p></sec><sec sec-type="subsection" id="sec2.3"><title>2.3. Statistical Analysis</title><p>The results were represented as means &#x000b1; SEM. The data were analyzed using Microsoft Excel (Office 2000) and Sigma Stat Version 3.0. Differences in levels of serum lipid levels were evaluated by using paired <italic>t</italic>-test. Differences in serum resistin and leptin levels were evaluated by mean percentage change from baseline.</p></sec></sec><sec id="sec3"><title>3. Results</title><sec sec-type="subsection" id="sec3.1"><title>3.1. Subject Demographics</title><p>
<xref ref-type="table" rid="tab1">Table 1 </xref>demonstrates the baseline demographics of the study population. The mean age of our subjects was 29 &#x000b1; 9 years. Ten out of 12 subjects identified themselves as of Caucasian ethnicity, while 1 each were from Hispanic and African American ethnicity. Four subjects identified themselves as active smokers.</p></sec><sec sec-type="subsection" id="sec3.2"><title>3.2. Changes in Clinical and Biochemical Markers in Response to Testosterone</title><p>As expected, serum testosterone values increased after the initiation of testosterone therapy (<italic>P</italic> &#x0003c; .001) (<xref ref-type="table" rid="tab2">Table 2</xref>). The increase in testosterone was accompanied by an increase in hematocrit (<italic>P</italic> &#x0003c; .001) (<xref ref-type="table" rid="tab2">Table 2</xref>). We did not observe any changes in the clinical parameters of body mass index and mean arterial pressure or in the biochemical parameters of the liver transaminases (SGOT/SGPT) or platelet count (<xref ref-type="table" rid="tab2">Table 2</xref>).</p></sec><sec sec-type="subsection" id="sec3.3"><title>3.3. Changes in Lipid Parameters</title><p>We observed a significant decrease in high-density lipoprotein (HDL) cholesterol (<italic>P</italic> &#x0003c; .001) but no significant changes in the other lipid parameters such as low-density lipoprotein (LDL), total cholesterol, or triglycerides (<xref ref-type="table" rid="tab2">Table 2</xref>). The serum resistin and leptin (<italic>n</italic> = 5) remained unchanged from 10.3 &#x000b1; 2.1 to 9.6 &#x000b1; 2.2&#x02009;ng/dL (<italic>P</italic> = .679) and 31.2 &#x000b1; 29.5 to 19.1 &#x000b1; 17.5&#x02009;ng/dL (a 25% reduction, <italic>P</italic> = .181), respectively (<xref ref-type="table" rid="tab2">Table 2</xref>).</p></sec></sec><sec id="sec4"><title>4. Discussion</title><p>Our study demonstrated a significant decrease in the concentration of HDL after 1 year of testosterone therapy in FTM transsexuals, as previously reported by other studies [<xref rid="B3" ref-type="bibr">3</xref>, <xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B15" ref-type="bibr">15</xref>]. The serum LDL, TG, and TC did not show a significant change. The leptin and resistin levels did not demonstrate a significant change, owing to the small number of subjects. There was no increase in mean arterial blood pressure or change in BMI after two years of therapy. Liver enzymes and fasting blood glucose levels remained unchanged, while as expected there was a rise in hematocrit.</p><p> Several studies have examined the effects of testosterone on lipid concentrations in females and in FTM transsexuals. Goh et al. demonstrated a decrease in HDL and an increase in LDL, TG, and TC levels after long-term testosterone therapy in women [<xref rid="B4" ref-type="bibr">4</xref>]. Mueller et al. demonstrated an increased serum TG concentration and a decreased HDL concentration without any change in LDL in FTM subjects treated with testosterone [<xref rid="B15" ref-type="bibr">15</xref>]. Similarly, Elbers et al. demonstrated a decreased HDL and LDL particle size and increased TG concentration after testosterone administration in FTM transsexuals [<xref rid="B8" ref-type="bibr">8</xref>]. In contrast, Jacobeit et al. [<xref rid="B16" ref-type="bibr">16</xref>] demonstrated that testosterone therapy in FTM transsexuals resulted in a statistically significant decrease in the level of TC and LDL, with no change in HDL. A recent meta-analysis of testosterone therapy in FTM transsexuals demonstrated an increase in TG and decrease in HDL in FTM transsexuals [<xref rid="B3" ref-type="bibr">3</xref>]. Of importance, the increase in TG levels was more significant in studies which had longer followup times [<xref rid="B3" ref-type="bibr">3</xref>]. Our study is consistent with the majority of studies that demonstrate a reduced HDL level but we were unable to demonstrate a change in TG levels likely due to the short-term nature of our study. </p><p> Despite seemingly adverse changes in the lipid profile from testosterone administration in FTM transsexuals, testosterone administration has not been associated with increased cardiovascular morbidity or mortality in FTM transsexuals [<xref rid="B3" ref-type="bibr">3</xref>, <xref rid="B7" ref-type="bibr">7</xref>]. Therefore, in a subset of our patients, we investigated effects of testosterone supplementation on adipocyte hormones that are putative cardiovascular risk factors. Leptin is an adipocyte hormone that signals receptors in hypothalamus to decrease food intake and stimulates energy expenditure [<xref rid="B17" ref-type="bibr">17</xref>]. Studies have demonstrated leptin to be an independent risk factor for stroke and myocardial infarction after controlling for obesity status [<xref rid="B18" ref-type="bibr">18</xref>, <xref rid="B19" ref-type="bibr">19</xref>]. Leptin administration has been reported to raise serum TG, LDL, and TC levels [<xref rid="B20" ref-type="bibr">20</xref>]. Supraphysiological doses of testosterone in FTM transsexuals have been reported to reduce plasma leptin concentration [<xref rid="B11" ref-type="bibr">11</xref>, <xref rid="B21" ref-type="bibr">21</xref>]. However, Resmini et al. [<xref rid="B12" ref-type="bibr">12</xref>] reported a strong interindividual variability in response of plasma leptin levels to testosterone therapy and, hence, failed to show a significant posttreatment change. Similarly, in a subset of our subjects, we found a 25% decrease in plasma leptin concentration with testosterone therapy which did not reach statistical significance likely to the small number of subjects evaluated. Therefore, we can only conclude that larger and more long-term studies need to be conducted to confirm the effects of testosterone on leptin concentrations in FTM transsexuals.</p><p>Resistin is an adipocytokine that is associated with obesity-mediated insulin resistance [<xref rid="B22" ref-type="bibr">22</xref>] and increased cardiovascular risk [<xref rid="B23" ref-type="bibr">23</xref>]. We are not aware of a previously published study to evaluate testosterone therapy on resistin concentrations in FTM transsexuals. Data from females with elevated endogenous androgen levels as occurring in PCOS have attempted to evaluate the relationship between resistin and androgen concentrations. Seow et al. found no difference in serum resistin levels in patients with and without PCOS and there was no correlation between serum resistin and testosterone levels [<xref rid="B24" ref-type="bibr">24</xref>]. However in contrast, Carmina et al. reported elevated plasma resistin levels in PCOS patients [<xref rid="B13" ref-type="bibr">13</xref>]. Finally, Yilmaz et al. [<xref rid="B25" ref-type="bibr">25</xref>] reported that plasma resistin levels were not associated with androgen concentrations in women with PCOS [<xref rid="B25" ref-type="bibr">25</xref>]. In summary, few studies have evaluated the relationship between endogenous testosterone levels or testosterone therapy on resistin concentrations. Our study did not demonstrate any significant differences in the resistin levels after administration of testosterone in FTM transsexuals.</p></sec><sec id="sec5"><title>5. Conclusion</title><p>Testosterone therapy in FTM transsexuals results in a more atherogenic lipid profile by significantly decreasing HDL. Although limited by the population size, our preliminary study found that initiation of testosterone therapy in female-to-male (FTM) transsexuals may lower plasma leptin levels. Long-term studies are needed to monitor cardiovascular events in FTM transsexuals on testosterone therapy to determine if these changes in the lipid profile and adipocyte hormones translate into increased cardiovascular events.</p></sec><sec id="sec6"><title> Conflict of Interest</title><p>The authors report no conflict of interest.</p></sec></body><back><ack><title>Acknowledgments</title><p>The investigators acknowledge the assistance of Dr. Junqiang Tian and the staff at the Boston University GCRC in the conduct of this study. The study was supported by NIH Grant no. M01RR000533.</p></ack><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hembree</surname><given-names>WC</given-names></name><name><surname>Cohen-Kettenis</surname><given-names>P</given-names></name><name><surname>Delemarre-Van De Waal</surname><given-names>HA</given-names></name><etal/></person-group><article-title>Endocrine treatment of transsexual persons: an endocrine society clinical practice guideline</article-title><source><italic>Journal of Clinical Endocrinology and Metabolism</italic></source><year>2009</year><volume>94</volume><issue>9</issue><fpage>3132</fpage><lpage>3154</lpage><pub-id pub-id-type="pmid">19509099</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tangpricha</surname><given-names>V</given-names></name><name><surname>Ducharme</surname><given-names>SH</given-names></name><name><surname>Barber</surname><given-names>TW</given-names></name><name><surname>Chipkin</surname><given-names>SR</given-names></name></person-group><article-title>Endocrinologic treatment of gender identity disorders</article-title><source><italic>Endocrine Practice</italic></source><year>2003</year><volume>9</volume><issue>1</issue><fpage>12</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">12917087</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elamin</surname><given-names>MB</given-names></name><name><surname>Garcia</surname><given-names>MZ</given-names></name><name><surname>Murad</surname><given-names>MH</given-names></name><name><surname>Erwin</surname><given-names>PJ</given-names></name><name><surname>Montori</surname><given-names>VM</given-names></name></person-group><article-title>Effect of sex steroid use on cardiovascular risk in transsexual individuals: a systematic review and meta-analyses</article-title><source><italic>Clinical Endocrinology</italic></source><year>2010</year><volume>72</volume><issue>1</issue><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">19473174</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goh</surname><given-names>HH</given-names></name><name><surname>Loke</surname><given-names>DFM</given-names></name><name><surname>Ratnam</surname><given-names>SS</given-names></name></person-group><article-title>The impact of long-term testosterone replacement therapy on lipid and lipoprotein profiles in women</article-title><source><italic>Maturitas</italic></source><year>1995</year><volume>21</volume><issue>1</issue><fpage>65</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">7731386</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giltay</surname><given-names>EJ</given-names></name><name><surname>Toorians</surname><given-names>AWFT</given-names></name><name><surname>Sarabjitsingh</surname><given-names>AR</given-names></name><name><surname>de Vries</surname><given-names>NA</given-names></name><name><surname>Gooren</surname><given-names>LJG</given-names></name></person-group><article-title>Established risk factors for coronary heart disease are unrelated to androgen-induced baldness in female-to-male transsexuals</article-title><source><italic>Journal of Endocrinology</italic></source><year>2004</year><volume>180</volume><issue>1</issue><fpage>107</fpage><lpage>112</lpage><pub-id pub-id-type="pmid">14709149</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacobeit</surname><given-names>JW</given-names></name><name><surname>Gooren</surname><given-names>LJ</given-names></name><name><surname>Schulte</surname><given-names>HM</given-names></name></person-group><article-title>Safety aspects of 36 months of administration of long-acting intramuscular testosterone undecanoate for treatment of female-to-male transgender individuals</article-title><source><italic>European Journal of Endocrinology</italic></source><year>2009</year><volume>161</volume><issue>5</issue><fpage>795</fpage><lpage>798</lpage><pub-id pub-id-type="pmid">19749027</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gooren</surname><given-names>LJ</given-names></name><name><surname>Giltay</surname><given-names>EJ</given-names></name><name><surname>Bunck</surname><given-names>MC</given-names></name></person-group><article-title>Long-term treatment of transsexuals with cross-sex hormones: extensive personal experience</article-title><source><italic>Journal of Clinical Endocrinology and Metabolism</italic></source><year>2008</year><volume>93</volume><issue>1</issue><fpage>19</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">17986639</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elbers</surname><given-names>JMH</given-names></name><name><surname>Giltay</surname><given-names>EJ</given-names></name><name><surname>Teerlink</surname><given-names>T</given-names></name><etal/></person-group><article-title>Effects of sex steroids on components of the insulin resistance syndrome in transsexual subjects</article-title><source><italic>Clinical Endocrinology</italic></source><year>2003</year><volume>58</volume><issue>5</issue><fpage>562</fpage><lpage>571</lpage><pub-id pub-id-type="pmid">12699437</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elbers</surname><given-names>JMH</given-names></name><name><surname>De Jong</surname><given-names>S</given-names></name><name><surname>Teerlink</surname><given-names>T</given-names></name><name><surname>Asscheman</surname><given-names>H</given-names></name><name><surname>Seidell</surname><given-names>JC</given-names></name><name><surname>Gooren</surname><given-names>LJG</given-names></name></person-group><article-title>Changes in fat cell size and in vitro lipolytic activity of abdominal and gluteal adipocytes after a one-year cross-sex hormone administration in transsexuals</article-title><source><italic>Metabolism</italic></source><year>1999</year><volume>48</volume><issue>11</issue><fpage>1371</fpage><lpage>1377</lpage><pub-id pub-id-type="pmid">10582544</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Page</surname><given-names>ST</given-names></name><name><surname>Herbst</surname><given-names>KL</given-names></name><name><surname>Amory</surname><given-names>JK</given-names></name><etal/></person-group><article-title>Testosterone administration suppresses adiponectin levels in men</article-title><source><italic>Journal of Andrology</italic></source><year>2005</year><volume>26</volume><issue>1</issue><fpage>85</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">15611571</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elbers</surname><given-names>JMH</given-names></name><name><surname>Asscheman</surname><given-names>H</given-names></name><name><surname>Seidell</surname><given-names>JC</given-names></name><name><surname>Fr&#x000f6;lich</surname><given-names>M</given-names></name><name><surname>Meinders</surname><given-names>AE</given-names></name><name><surname>Gooren</surname><given-names>LJG</given-names></name></person-group><article-title>Reversal of the sex difference in serum leptin levels upon cross-sex hormone administration in transsexuals</article-title><source><italic>Journal of Clinical Endocrinology and Metabolism</italic></source><year>1997</year><volume>82</volume><issue>10</issue><fpage>3267</fpage><lpage>3270</lpage><pub-id pub-id-type="pmid">9329351</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Resmini</surname><given-names>E</given-names></name><name><surname>Andraghetti</surname><given-names>G</given-names></name><name><surname>Rebora</surname><given-names>A</given-names></name><etal/></person-group><article-title>Leptin, ghrelin, and adiponectin evaluation in transsexual subjects during hormonal treatments</article-title><source><italic>Journal of Andrology</italic></source><year>2008</year><volume>29</volume><issue>5</issue><fpage>580</fpage><lpage>585</lpage><pub-id pub-id-type="pmid">18421069</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carmina</surname><given-names>E</given-names></name><name><surname>Orio</surname><given-names>F</given-names></name><name><surname>Palomba</surname><given-names>S</given-names></name><etal/></person-group><article-title>Evidence for altered adipocyte function in polycystic ovary syndrome</article-title><source><italic>European Journal of Endocrinology</italic></source><year>2005</year><volume>152</volume><issue>3</issue><fpage>389</fpage><lpage>394</lpage><pub-id pub-id-type="pmid">15757855</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turner</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>TC</given-names></name><name><surname>Barber</surname><given-names>TW</given-names></name><name><surname>Malabanan</surname><given-names>AO</given-names></name><name><surname>Holick</surname><given-names>MF</given-names></name><name><surname>Tangpricha</surname><given-names>V</given-names></name></person-group><article-title>Testosterone increases bone mineral density in female-to-male transsexuals: a case series of 15 subjects</article-title><source><italic>Clinical Endocrinology</italic></source><year>2004</year><volume>61</volume><issue>5</issue><fpage>560</fpage><lpage>566</lpage><pub-id pub-id-type="pmid">15521957</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mueller</surname><given-names>A</given-names></name><name><surname>Kiesewetter</surname><given-names>F</given-names></name><name><surname>Binder</surname><given-names>H</given-names></name><name><surname>Beckmann</surname><given-names>MW</given-names></name><name><surname>Dittrich</surname><given-names>R</given-names></name></person-group><article-title>Long-term administration of testosterone undecanoate every 3 months for testosterone supplementation in female-to-male transsexuals</article-title><source><italic>Journal of Clinical Endocrinology and Metabolism</italic></source><year>2007</year><volume>92</volume><issue>9</issue><fpage>3470</fpage><lpage>3475</lpage><pub-id pub-id-type="pmid">17579193</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacobeit</surname><given-names>JW</given-names></name><name><surname>Gooren</surname><given-names>LJ</given-names></name><name><surname>Schulte</surname><given-names>HM</given-names></name></person-group><article-title>Long-acting intramuscular testosterone undecanoate for treatment of female-to-male transgender individuals</article-title><source><italic>Journal of Sexual Medicine</italic></source><year>2007</year><volume>4</volume><issue>5</issue><fpage>1479</fpage><lpage>1484</lpage><pub-id pub-id-type="pmid">17635694</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mantzoros</surname><given-names>CS</given-names></name></person-group><article-title>The role of leptin in human obesity and disease: a review of current evidence</article-title><source><italic>Annals of Internal Medicine</italic></source><year>1999</year><volume>130</volume><issue>8</issue><fpage>671</fpage><lpage>680</lpage><pub-id pub-id-type="pmid">10215564</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sierra-Johnson</surname><given-names>J</given-names></name><name><surname>Romero-Corral</surname><given-names>A</given-names></name><name><surname>Lopez-Jimenez</surname><given-names>F</given-names></name><etal/></person-group><article-title>Relation of increased leptin concentrations to history of myocardial infarction and stroke in the United States population</article-title><source><italic>American Journal of Cardiology</italic></source><year>2007</year><volume>100</volume><issue>2</issue><fpage>234</fpage><lpage>239</lpage><pub-id pub-id-type="pmid">17631076</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Romero-Corral</surname><given-names>A</given-names></name><name><surname>Sierra-Johnson</surname><given-names>J</given-names></name><name><surname>Lopez-Jimenez</surname><given-names>F</given-names></name><etal/></person-group><article-title>Relationships between leptin and C-reactive protein with cardiovascular disease in the adult general population</article-title><source><italic>Nature Clinical Practice Cardiovascular Medicine</italic></source><year>2008</year><volume>5</volume><issue>7</issue><fpage>418</fpage><lpage>425</lpage></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Javor</surname><given-names>ED</given-names></name><name><surname>Ghany</surname><given-names>MG</given-names></name><name><surname>Cochran</surname><given-names>EK</given-names></name><etal/></person-group><article-title>Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy</article-title><source><italic>Hepatology</italic></source><year>2005</year><volume>41</volume><issue>4</issue><fpage>753</fpage><lpage>760</lpage><pub-id pub-id-type="pmid">15791619</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berra</surname><given-names>M</given-names></name><name><surname>Armillotta</surname><given-names>F</given-names></name><name><surname>D&#x02019;emidio</surname><given-names>L</given-names></name><etal/></person-group><article-title>Testosterone decreases adiponectin levels in female to male transsexuals</article-title><source><italic>Asian Journal of Andrology</italic></source><year>2006</year><volume>8</volume><issue>6</issue><fpage>725</fpage><lpage>729</lpage><pub-id pub-id-type="pmid">16855767</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steppan</surname><given-names>CM</given-names></name><name><surname>Bailey</surname><given-names>ST</given-names></name><name><surname>Bhat</surname><given-names>S</given-names></name><etal/></person-group><article-title>The hormone resistin links obesity to diabetes</article-title><source><italic>Nature</italic></source><year>2001</year><volume>409</volume><issue>6818</issue><fpage>307</fpage><lpage>312</lpage><pub-id pub-id-type="pmid">11201732</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Norata</surname><given-names>GD</given-names></name><name><surname>Ongari</surname><given-names>M</given-names></name><name><surname>Garlaschelli</surname><given-names>K</given-names></name><name><surname>Raselli</surname><given-names>S</given-names></name><name><surname>Grigore</surname><given-names>L</given-names></name><name><surname>Catapano</surname><given-names>AL</given-names></name></person-group><article-title>Plasma resistin levels correlate with determinants of the metabolic syndrome</article-title><source><italic>European Journal of Endocrinology</italic></source><year>2007</year><volume>156</volume><issue>2</issue><fpage>279</fpage><lpage>284</lpage><pub-id pub-id-type="pmid">17287419</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seow</surname><given-names>K-M</given-names></name><name><surname>Juan</surname><given-names>C-C</given-names></name><name><surname>Wu</surname><given-names>L-Y</given-names></name><etal/></person-group><article-title>Serum and adipocyte resistin in polycystic ovary syndrome with insulin resistance</article-title><source><italic>Human Reproduction</italic></source><year>2004</year><volume>19</volume><issue>1</issue><fpage>48</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">14688155</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yilmaz</surname><given-names>M</given-names></name><name><surname>Bukan</surname><given-names>N</given-names></name><name><surname>Demirc</surname><given-names>H</given-names></name><etal/></person-group><article-title>Serum resistin and adiponectin levels in women with polycystic ovary syndrome</article-title><source><italic>Gynecological Endocrinology</italic></source><year>2009</year><volume>25</volume><issue>4</issue><fpage>246</fpage><lpage>252</lpage><pub-id pub-id-type="pmid">19408174</pub-id></element-citation></ref></ref-list></back><floats-group><table-wrap id="tab1" position="float"><label>Table 1</label><caption><p>Demographic background of female to male transsexuals prior to the initiation of testosterone therapy (<italic>n</italic> = 12).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">
</th><th align="center" rowspan="1" colspan="1">
<italic>N</italic> = 12</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age (years)</td><td align="center" rowspan="1" colspan="1">29 &#x000b1; 9</td></tr><tr><td align="left" rowspan="1" colspan="1">Race (<italic>n</italic>) African/Caucasian/Hispanic</td><td align="center" rowspan="1" colspan="1">1/10/1</td></tr><tr><td align="left" rowspan="1" colspan="1">Smokers (<italic>n</italic>)</td><td align="center" rowspan="1" colspan="1">4</td></tr></tbody></table></table-wrap><table-wrap id="tab2" position="float"><label>Table 2</label><caption><p>Biochemical changes in response to 12 months of testosterone therapy in female-to-male transsexuals, including changes in lipid profile and markers of insulin resistance. Mean &#x000b1; SEM, <italic>N</italic> = 12 unless specified.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">
</th><th align="center" rowspan="1" colspan="1">Prior to Testosterone</th><th align="center" rowspan="1" colspan="1">12 months</th><th align="center" rowspan="1" colspan="1">
<italic>P</italic>-value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Body Mass Index (BMI) (kg/m<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">27.5 &#x000b1; 5.2</td><td align="center" rowspan="1" colspan="1">27.6 &#x000b1; 3.9</td><td align="center" rowspan="1" colspan="1">.47</td></tr><tr><td align="center" colspan="4" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Mean Arterial Pressure (MAP (mm Hg)</td><td align="center" rowspan="1" colspan="1">87 &#x000b1; 14</td><td align="center" rowspan="1" colspan="1">91 &#x000b1; 16</td><td align="center" rowspan="1" colspan="1">.16</td></tr><tr><td align="center" colspan="4" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Serum Glutamic Oxaloacetic Transaminase (SGOT) (IU/L)</td><td align="center" rowspan="1" colspan="1">21 &#x000b1; 5</td><td align="center" rowspan="1" colspan="1">25 &#x000b1; 7</td><td align="center" rowspan="1" colspan="1">.22</td></tr><tr><td align="center" colspan="4" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Serum Glutamate Pyruvate Transaminase (SGPT) (IU/L)</td><td align="center" rowspan="1" colspan="1">19 &#x000b1; 7</td><td align="center" rowspan="1" colspan="1">24 &#x000b1; 10</td><td align="center" rowspan="1" colspan="1">.22</td></tr><tr><td align="center" colspan="4" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Serum Total Testosterone (nmol/L)</td><td align="center" rowspan="1" colspan="1">3.4 &#x000b1; 3.0</td><td align="center" rowspan="1" colspan="1">34.6 &#x000b1; 8.5</td><td align="center" rowspan="1" colspan="1">&#x0003c;.001</td></tr><tr><td align="center" colspan="4" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Hematocrit (%)</td><td align="center" rowspan="1" colspan="1">40 &#x000b1; 2</td><td align="center" rowspan="1" colspan="1">45 &#x000b1; 5</td><td align="center" rowspan="1" colspan="1">&#x0003c;.001</td></tr><tr><td align="center" colspan="4" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Platelets (&#x000d7;1000/<italic>&#x003bc;</italic>L)</td><td align="center" rowspan="1" colspan="1">282 &#x000b1; 44</td><td align="center" rowspan="1" colspan="1">266 &#x000b1; 38</td><td align="center" rowspan="1" colspan="1">.21</td></tr><tr><td align="center" colspan="4" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">High Density Lipoprotein (HDL) (mg/dL)</td><td align="center" rowspan="1" colspan="1">52 &#x000b1; 11</td><td align="center" rowspan="1" colspan="1">&#x02009;&#x02009;40 &#x000b1; 7</td><td align="center" rowspan="1" colspan="1">&#x0003c;.001</td></tr><tr><td align="center" colspan="4" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Low Density Lipoprotein (LDL) (mg/dL)</td><td align="center" rowspan="1" colspan="1">113 &#x000b1; 22</td><td align="center" rowspan="1" colspan="1">121 &#x000b1; 29</td><td align="center" rowspan="1" colspan="1">.32</td></tr><tr><td align="center" colspan="4" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Total Cholesterol (mg/dL)</td><td align="center" rowspan="1" colspan="1">184 &#x000b1; 26</td><td align="center" rowspan="1" colspan="1">181 &#x000b1; 34</td><td align="center" rowspan="1" colspan="1">.77</td></tr><tr><td align="center" colspan="4" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Triglycerides (mg/dL)</td><td align="center" rowspan="1" colspan="1">92 &#x000b1; 72</td><td align="center" rowspan="1" colspan="1">94 &#x000b1; 41</td><td align="center" rowspan="1" colspan="1">.91</td></tr><tr><td align="center" colspan="4" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Leptin (ng/dL)</td><td align="center" rowspan="1" colspan="1">31.2 &#x000b1; 29.5</td><td align="center" rowspan="1" colspan="1">19.1 &#x000b1; 17.5</td><td align="center" rowspan="1" colspan="1">.18</td></tr><tr><td align="center" colspan="4" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Resistin (ng/dL)</td><td align="center" rowspan="1" colspan="1">10.3 &#x000b1; 2.1</td><td align="center" rowspan="1" colspan="1">9.6 &#x000b1; 2.2</td><td align="center" rowspan="1" colspan="1">.68</td></tr><tr><td align="center" colspan="4" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Fasting glucose (mg/dL)</td><td align="center" rowspan="1" colspan="1">86 &#x000b1; 12</td><td align="center" rowspan="1" colspan="1">&#x02009;&#x02009;83 &#x000b1; 11</td><td align="center" rowspan="1" colspan="1">.43</td></tr></tbody></table></table-wrap></floats-group></article>